Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New valve procedure aims to fix leaky heart in pump patients

NCT ID NCT07363473

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new device called the J-Valve Transfemoral System in 50 adults who have a heart pump (LVAD) and a severely leaking aortic valve. The valve is replaced through a blood vessel, avoiding open-heart surgery. The goal is to see if it safely stops the leak and improves heart function and survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
J-Valve Transfemoral System (a replacement heart valve delivered through a blood vessel)
What this could lead to
If it works, this could offer a less invasive way to fix a leaking aortic valve in people who already have a heart pump, potentially improving their heart function and quality of life.
What could go wrong
This is an early study with only 50 participants, so results may not apply to everyone. Risks include valve movement, need for a second valve, or death.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Nov 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult with durable left ventricular assist device (LVAD) support and clinically significant AR (grade 4 or higher as assessed by core lab using TTE and adjunct TEE, if necessary) leading to LVAD dysfunction 2. Symptomatic according to New York Heart Association (NYHA) functional class II or higher 3. High risk for surgery as judged by a multi-disciplinary heart team 4. Suitable anatomy to accommodate the insertion, delivery, and deployment of the study devices (see anatomic exclusions below) 5. Written informed consent and agreement to comply with all required follow-up visits at investigational site Exclusion Criteria: 1. Prior aortic valve replacement or repair 2. Aortic valve stenosis \> moderate as assessed by core lab 3. Severe mitral valve or tricuspid valve regurgitation as assessed by core lab 4. Severe mitral valve or tricuspid valve stenosis as assessed by core lab 5. Active infection requiring current antibiotic therapy, including infective endocarditis 6. Cardiac imaging evidence of cardiac mass, thrombus or vegetation 7. Inability to tolerate or a condition precluding treatment with antithrombotic (antiplatelet, anticoagulant) therapy 8. Renal insufficiency (eGFR \<25 mL/min/1.73m2) or end stage renal disease requiring chronic dialysis 9. Cirrhosis (Child-Pugh Class B or C) 10. Leukopenia (WBC \<3000 cells/mcL), thrombocytopenia (platelet count \<50,000 cells/mcL), anemia (hemoglobin \<9 g/dL), history of bleeding diathesis, coagulopathy, or hypercoagulable state (unless therapeutically stable) 11. Known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, clopidogrel, Nitinol (Nickel, Titanium) or sensitivity to contrast media which cannot be adequately premedicated 12. Clinically significant untreated coronary artery disease requiring revascularization or anticipated coronary revascularization procedure within 12 months post-index procedure 13. Acute myocardial infarction within 30 days prior to index procedure 14. PCI within 30 days prior to index procedure 15. Carotid intervention within 6 weeks prior to index procedure or carotid artery disease requiring intervention 16. Previous, or planned, other surgical or interventional procedures within 30 days before, during, or within 30 days after the index procedure 17. Uncontrolled atrial fibrillation 18. Severe right ventricular (RV) dysfunction or chronic inotrope support (\>30 days) 19. Severe pulmonary hypertension (systolic pulmonary artery pressure \>80 mmHg measured by right heart catheterization) 20. Severe chronic obstructive pulmonary disease (COPD) requiring chronic oral steroids or requiring continuous home oxygen 21. Stroke (cerebrovascular accident, CVA), transient ischemic attack (TIA) or neurological signs and symptoms attributed to carotid or vertebrobasilar disease within 90 days prior to index procedure 22. Estimated life expectancy of less than 12 months 23. Pregnancy or intent to become pregnant prior to completion of all protocol follow-up requirements 24. Participation in another investigational study that has not reached its primary endpoint 25. Considered to be part of a vulnerable population Anatomic Exclusions: 1. Ascending aortic diameter ≥5.5 cm as assessed by core lab 2. Aortic annulus perimeter \<57 mm or \>104 mm as assessed by core lab 3. Inappropriate anatomy for femoral introduction and delivery of the study system 4. Congenital aortic valve disease including unicuspid, bicuspid, or quadricuspid aortic valve anatomy as assessed by core lab 5. Congenital univentricle or other condition that, in the opinion of the investigator and/or consulting physician, may constitute an unwarranted surgical risk 6. Excessive aortic valve prolapse or leaflet deterioration that would preclude proper seating of the implant in the aortic annulus 7. Abdominal/thoracic aortic aneurysm ≥5.0 cm as assessed by core lab 8. Aorto-iliac disease requiring intervention to facilitate delivery of access sheath 9. Excessive tortuosity of delivery system pathway, defined as severe tortuosity of multiple vessels including iliofemoral, thoracoabdominal aorta, aortic arch, and/or LV-aortic root angle \>80°

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic insufficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.